SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: Platform Specialty Products Corporation (Note: Input metadata listed "Element Solutions Inc," but the filing text identifies the registrant as Platform Specialty Products Corporation).
Date of Report: September 12, 2016
Date of Event: September 9, 2016
Context: The company entered into a Settlement Agreement and Release with Permira Advisers LLC and related entities (the "Permira Entities") regarding obligations under a 2014 Share Purchase Agreement (SPA) for the acquisition of Arysta LifeScience Limited.
Key Financial Metrics and Transaction Details
This filing reports a specific settlement transaction rather than periodic financial performance metrics (revenue, profit, cash flow). Key financial terms of the agreement include:
- Original Obligation: $600 million portion of the purchase price paid in 600,000 shares of Series B Convertible Preferred Stock with a $1,000 liquidation preference per share.
- Make Whole Provision: Under the original SPA, Platform was obligated to pay the difference if the conversion value of the Preferred Stock was less than $600 million. The current conversion value is below this threshold.
- Settlement Cash Payment: Platform may settle all obligations related to the Make Whole Payment and Preferred Stock for a fixed cash payment of $460 million.
- Settlement Window: October 20, 2016, to December 15, 2016.
- Equity Conversion: Nalozo S.à.r.l. will convert a portion of the Preferred Stock resulting in the issuance of 5.5 million shares of Platform's common stock.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Agreements
The primary material change is the modification of the settlement mechanism for the Arysta LifeScience acquisition earn-out/contingent consideration:
- Alternative Settlement: Replaces the variable "Make Whole Payment" obligation with a fixed $460 million cash payment.
- Release of Claims: Both parties have released each other from claims related to the original SPA.
- Timing: The settlement is contingent on execution within the specified window in late 2016.
Guidance, Outlook, and Risks
Management Commentary: The filing contains standard forward-looking statements regarding risks and uncertainties. Management does not undertake a duty to update this information.
Risks and Contingencies:
- Actual results may differ materially from anticipated results due to risks beyond Platform's control.
- Investors are directed to the "Risk Factors" section of the 2015 Form 10-K and 2016 Form 10-Q filings for additional details on factors impacting operations.
Investor Verification Checklist
- Verify the exact timing of the $460 million cash payment within the October 20 to December 15, 2016 window.
- Confirm the impact of the 5.5 million new common shares on existing shareholder dilution.
- Review the full text of the Settlement Agreement (Exhibit 2.1) for any conditions precedent to the cash payment.
- Assess the company's current liquidity position to ensure it can fund the $460 million settlement without impacting operations.
- Check subsequent filings for confirmation that the settlement was executed within the deadline.